Sep. 11, 2015, 12:44 PM
Jun. 9, 2015, 5:37 PM
May 7, 2015, 5:12 PM
- Aceto (NASDAQ:ACET): FQ3 EPS of $0.29 in-line.
- Revenue of $145.8M (+16.8% Y/Y) beats by $5.8M.
- Shares +4.33% AH.
May 19, 2014, 12:45 PM
Feb. 7, 2014, 12:25 PM
- Aceto (ACET -11.9%) says financial media outlets have misreported that the company missed revenue forecasts by $30.5M; in fact, revenue in the most recent quarter rose 2.2% Y/Y to $116.5M, which was $2.7M below the correct estimate.
- ACET says reported EPS of $0.24 was in line with estimates and a 41% Y/Y increase.
Nov. 8, 2013, 12:53 PM
Nov. 27, 2012, 10:51 AM
Aceto Pharmaceutical (ACET +2.1%) gets a boost today from what appears to be a delayed reaction to yesterday's launch of its generic Clindamycin Palmitate Hydrochloride for Oral Solution, an FDA approved generic version of Pfizer's (PFE -0.6%) Cleocin Pediatric. U.S. market sales for Clindamycin Palmitate Hydrochloride - which is an antibiotic that is used to treat serious bacterial infections - were approximately $59M for the twelve months ended June 30.| Nov. 27, 2012, 10:51 AM